Trials / Completed
CompletedNCT00657904
Bicalutamide (Casodex™) Versus Placebo in Patients With Early Prostate Cancer
A Randomized Double-Blind Comparative Trial of Bicalutamide (Casodex™) Versus Placebo in Patients With Early Prostate Cancer.
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 3,618 (actual)
- Sponsor
- AstraZeneca · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this trial is to study the effect - in terms of time to progression and overall survival - of 2 years of adjuvant bicalutamide 150mg monotherapy, versus placebo, in subjects with histologically or cytologically confirmed non-metastatic adenocarcinoma of the prostate gland.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Bicalutamide | 150mg daily |
| DRUG | Placebo | once daily |
Timeline
- Start date
- 1995-08-01
- Primary completion
- 2008-07-01
- Completion
- 2008-08-01
- First posted
- 2008-04-14
- Last updated
- 2012-06-06
Locations
85 sites across 2 countries: United States, Canada
Source: ClinicalTrials.gov record NCT00657904. Inclusion in this directory is not an endorsement.